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Summary
 
Although implicated in the clinical expression of human visceral leishmaniasis, a disease-exac-
erbating T helper cell 2 (Th2)-associated immune response involving interleukin-4 (IL-4) and/
or IL-10 is not readily detectable in experimental visceral infection. To overcome this obstacle
to analyzing visceral 
 
Leishmania donovani
 
 in this relevant immunopathogenetic environment,
we sought a model in which a Th2 response induces noncuring infection. Four initial ap-
proaches were tested primarily in BALB/c mice which control intracellular 
 
L. donovani
 
 via an
IL-12– and interferon-
 
g
 
 (IFN-
 
g
 
)–dependent Th1 mechanism: (
 
a
 
) modifying the cytokine mi-
lieu when the parasite is first encountered (treatment with exogenous IL-4 or anti–IL-12), (
 
b
 
)
providing sustained endogenous exposure to a Th2 cytokine (infection of IL-4 transgenic
mice), (
 
c
 
) increasing the parasite challenge inoculum, and (
 
d
 
) injecting heat-killed 
 
L. major
 
 pro-
mastigotes (HKLMP) to induce a cross-reactive Th2 response to live 
 
L. donovani
 
. Only the last
approach generated a functional Th2-type response that induced disease exacerbation accom-
panied by inhibition of tissue granuloma assembly. In HKLMP-primed BALB/c mice, prophy-
laxis with anti–IL-4, anti–IL-10, or exogenous IL-12 (but not IFN-
 
g
 
) readily restored resis-
tance. In primed mice with established visceral infection, treatment with either IL-12 or IFN-
 
g
 
also successfully induced antileishmanial activity. The results in this model (
 
a
 
) suggest that
rather than acting alone, IL-4 and IL-10 may act in concert to prevent acquisition of resistance
to 
 
L. donovani
 
, (
 
b
 
) reemphasize the capacity of IL-12 to reverse early Th2-related effects, and (
 
c
 
)
demonstrate that Th1 cytokines (IL-12, IFN-
 
g
 
) have therapeutic action in an established sys-
temic infection despite the presence of a disease-exacerbating Th2-type response.
 
E
 
merging data derived from patients with visceral leish-
maniasis, a disseminated intracellular protozoal infection
primarily caused by 
 
Leishmania donovani
 
 or 
 
Leishmania cha-
gasi
 
, suggest that clinically apparent or progressive disease
may be related to preferential expression of a downregulat-
ing Th2-associated immune response (1–11). This mecha-
nism, which involves the action of suppressive cytokines
including IL-4, IL-10, and perhaps other soluble factors
(12–15), has been thoroughly characterized in a BALB/c
mouse model of uncontrolled cutaneous infection caused
by 
 
Leishmania major
 
 (12, 13, 16, 17) and in a distinct model of
cutaneous infection induced by 
 
Leishmania mexicana
 
 (18, 19).
Although 
 
L. donovani
 
 and 
 
L. chagasi
 
 also readily parasitize
and/or cause noncuring visceral infection in inbred mice
(20–25), these 
 
Leishmania
 
 species do not regularly provoke
an active, functional Th2 response in experimental infec-
tion as they seem to induce in human disease (1–3, 9–11).
The one reported exception is in coat pigment mutant
C57BL/6 
 
ep
 
/
 
ep
 
 (pale ear) mice in which noncuring 
 
L.
donovani 
 
infection is related to multiple host defense defects
including a partially active Th2 cell response (24). However,
in other models, it has been difficult to detect or assign a
pathogenic role to this suppressive mechanism. In B10.D2
mice, for example, noncuring 
 
L. donovani
 
 infection has
been ascribed to the failure to properly express a Th1-asso-
ciated response rather than to pathologic activity of a Th2
mechanism (23). In addition, although 
 
L. donovani
 
 does in-
duce both IL-4 and IL-10 expression in infected tissues of
initially susceptible BALB/c mice, this response does not
expand and is rapidly overshadowed by a protective Th1-
associated mechanism (26). The latter response, dependent
upon IL-12 and IFN-
 
g
 
 (27, 28), induces macrophage acti-
vation and mediates acquisition of resistance and eventual
resolution of infection (22). The course of visceral 
 
L. chagasi
 
infection in BALB/c mice also closely mimics that of 
 
L.
donovani
 
, and mice express a susceptible but ultimately self-
healing phenotype (25). In the 
 
L. chagasi
 
 model, initially
suppressed Th1 activity (IFN-
 
g
 
 secretion) is apparently not
related to either IL-4 or IL-10 (25). Finally, rather than be-
ing less susceptible to 
 
L. donovani
 
, IL-4 gene disrupted 129/
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3
 
 C57BL/6 mice, in which Th2-associated cytokine
responses are blocked (29), show similar, rather than lower,
parasite burdens in comparison to wild-type controls (19).
Despite the preceding experience, studying 
 
L. donovani
 
experimentally in the presence of an active Th2 response is
worthwhile in view of the apparent clinical relevance of
this mechanism to human visceral infection (1–3, 7–10).
Therefore, we tested a variety of approaches to develop an
 
L. donovani
 
-Th2 response model.
 
Materials and Methods
 
Mice and Visceral Infection.
 
20–30 g female BALB/c and 129/
Sv/Ev mice were purchased from Charles Rivers Laboratories
(Wilmington, MA) and Taconic Farms (Germantown, NY), re-
spectively. IL-4 transgenic 129/Sv/PEP mice (30, 31) were bred
at DNAX (Palo Alto, CA). Groups of mice were challenged via
the tail vein with 10
 
7
 
 
 
L. donovani
 
 amastigotes (1 Sudan strain) ob-
tained from infected hamster spleen homogenates (22). The
course of visceral infection was measured using stained liver im-
prints, and microscopic counts were performed in a blinded fash-
ion. Liver parasite burdens, expressed as Leishman–Donovan units
(LDU)
 
1
 
, were calculated as the number of amastigotes per 500
nucleated hepatic cells 
 
3
 
 liver weight (g) (22). Formalin-fixed
liver sections, stained with hematoxylin and eosin, were scored
for granuloma formation as described (22).
 
Treatment of BALB/c Mice to Induce a Th2-associated Response.
 
Using the schedules described in the text and figure legends,
groups of four to five BALB/c mice were treated before 
 
L. dono-
vani
 
 challenge with (
 
a
 
) IL-4 complexed with anti–IL-4 (32) with or
without a single injection of anti–IFN-
 
g
 
, (
 
b
 
) anti–IL-12 (28, 33,
34), or (
 
c
 
) heat-killed 
 
L. major
 
 promastigotes (HKLPM; 35). 250 
 
m
 
g
of murine recombinant IL-4 (rIL-4; lot 941-90-1; 10
 
8
 
 U/ml,
DNAX)  was mixed in saline with 2.5 mg of rat anti–murine IL-4
mAb (11B.11; 10 mg/ml; DNAX) (32), and after 2 h on ice, 0.1
ml containing 10 
 
m
 
g of IL-4/100 
 
m
 
g of anti–IL-4 was injected in-
traperitoneally. This complexing prolongs the in vivo effects of
IL-4 (32). Some IL-4/anti–IL-4–treated mice also received an in-
traperitoneal injection of 100 
 
m
 
g of anti–murine IFN-
 
g
 
 mAb
(XMG1.2; 2.6 mg/ml; DNAX). 200 
 
m
 
g of normal sheep IgG or
200 
 
m
 
g of partially-purified sheep anti–mouse IL-12 IgG (5 mg/
ml; Genetics Institute, Cambridge, MA), provided by Dr. V. Van
Cleave (Genetics Institute; 34), was also injected three times per
week intraperitoneally as in earlier studies (28, 34). 
 
L. major
 
 pro-
mastigotes (WHO strain WHOM/
 
2
 
/173), maintained at room
temperature by weekly passage in medium 199 containing 30% fe-
tal bovine serum and antibiotics, were washed once, resuspended in
saline at 1.5 
 
3
 
 10
 
8
 
/ml, and then heated at 56
 
8
 
C for 60 min. Mice
were injected subcutaneously (thigh) once per week for 4 wk
with 0.1 ml containing saline alone or 1.5 
 
3
 
 10
 
7
 
 HKLMP, and
were challenged with 
 
L. donovani
 
 7 d after the fourth injection.
 
Anticytokine and Cytokine Treatments in HKLMP-primed BALB/c
Mice.
 
One day before 
 
L. donovani
 
 challenge (day 
 
2
 
1) and once
a week thereafter, HKLPM-primed mice were injected intraperi-
toneally with 1 mg of one of the following rat-derived prepara-
tions: normal IgG (26), anti–mouse IL-4 mAb (11B.11, lot 3-287-
880217; Biologic Response Modifiers Program, National Cancer
Institute, Fredrick, MD, provided by Dr. C. Reynolds, National
Cancer Institute; 26), anti–mouse IL-10 mAb (JES5-2A5, IgG1; 2.6
mg/ml; DNAX; 36), or anti–mouse 
 
b
 
-galactosidase (GL113,
IgG1; 6 mg/ml, DNAX) used as an isotype control. The latter
two mAb preparations were purified from tissue culture superna-
tants by ion exchange chromotography and gel filtration, and
each contained 
 
,
 
3 endotoxin units/mg of protein (
 
Limulus
 
 ag-
glutination assay).
As in earlier studies (37, 38), treatment with murine rIL-12
(1 
 
m
 
g/day), murine rIFN-
 
g
 
 (2 
 
3
 
 10
 
5
 
 U/day), or bovine serum
albumin (1 
 
m
 
g/day) as a control was administered continuously
for 7 d by subcutaneously implanted osmotic pumps (Alzet model
2001; Alza Corp., Palo Alto, CA). IL-12 (7.8 
 
3
 
 10
 
6
 
 U/mg) and
IFN-
 
g
 
 (2 
 
3
 
 10
 
7
 
 U/mg) were provided by Dr. J. Sypek (Genetics
Institute) and Amgen Biologicals (Thousand Oaks, CA), respec-
tively. To test cytokine effects as prophylaxis (34, 39), pumps de-
livering treatment for 7 d were inserted 4 h after 
 
L. donovani
 
 chal-
lenge. To test activity in established visceral infection, 7-d pumps
were implanted 3 wk after infection on day 
 
1
 
21. In all groups of
cytokine-treated mice, liver parasite burdens were measured at
the end of week 4 (day 
 
1
 
28). Percent inhibition of parasite repli-
cation at week 4 was determined as: (week 4 LDU in untreated
mice 
 
2
 
 week 4 LDU in treated mice) / week 4 LDU in un-
treated mice 
 
3
 
 100; percent parasite killing was determined as:
(week 3 LDU in untreated mice 
 
2
 
 week 4 LDU in treated mice) /
week 3 LDU in untreated mice 
 
3
 
 100 (38).
 
Assay for Serum IgE.
 
At the time mice were killed to deter-
mine parasite burdens, serum was obtained and frozen at 
 
2
 
70
 
8
 
C
until assayed for IgE by ELISA (40).
 
Statistical Analysis.
 
Differences between mean values were ana-
lyzed by a two-tailed Student’s 
 
t
 
 test (24).
 
Results
 
Outcome of Visceral Infection in Selected Mouse Populations
 
Initial efforts were directed at identifying a suitable
model of exacerbated visceral infection that was associated
with induction of a Th2-type response. Fig. 1 summarizes
preliminary experiments in which several different ap-
proaches were tested.
 
Effect of Single-dose Exogenous IL-4.
 
We focused first on
IL-4, a critical regulator of the Th2 response (12, 13, 19,
41), and tested the effect of altering the host cytokine mi-
lieu at the time the parasite was initially encountered.
BALB/c mice were pretreated once the day before infec-
tion (day 
 
2
 
1) with IL-4 complexed with anti–IL-4 with or
without one injection of anti–IFN-
 
g
 
. 4 wk after a single
dose of IL-4/anti–IL-4, the mean (6 SEM) serum level of
IgE (used as a marker for the effect of IL-4; 16, 42) in in-
fected mice was 12.3 6 1.8 mg/ml (n 5 4 mice) versus
4.7 6 0.4 mg/ml in infected controls (n 5 3 mice). As
shown in Fig. 1 A, whereas a single injection IL-4/anti–IL-4
exacerbated infection at week 2, this effect was short-lived
in treated animals. The addition of a single injection of
anti–IFN-g on day 21 did not alter the course of hepatic
infection in IL-4/anti–IL-4-treated mice (n 5 5 mice, data
not shown).
Effect of Multidose Exogenous IL-4. The effect of a single
injection of IL-4/anti–IL-4 at week 2, albeit brief, sug-
gested that the continued presence of IL-4 might enhance
the exacerbating action on L. donovani infection. Such an
approach using IL-4 alone transiently promoted L. major
1Abbreviations used in this paper: HKLPM, heat-killed L. major promasti-
gotes; LDU, Leishman–Donovan units; r, recombinant.869 Murray et al.
infection in resistant mice in one study (42) but not in an-
other (43). Therefore, starting on day 21 and for the first
4 wk thereafter, BALB/c mice were injected twice per
week with IL-4/anti–IL-4. Visceral infection was clearly
promoted during the 4-wk treatment period (Fig. 1 B).
However, once IL-4 injections were discontinued, this ef-
fect waned and infection came under control by week 8.
Effect of Endogenous IL-4. We next turned to IL-4 trans-
genic mice (30, 31) to test the effect of the sustained pres-
ence of endogenous IL-4. Despite a resistant 129/Sv back-
ground, these mice develop predominantly Th2-associated
responses to L. major and are susceptible to cutaneous infec-
tion (31). However, in the face of active secretion of IL-4, as
judged by a strikingly elevated serum IgE concentration 4
wk after infection (189 6 35 mg/ml, n 5 5 mice), IL-4
transgenic mice resisted and controlled L. donovani similar to
normal 129/Sv/Ev mice (Fig. 1 C). In these latter control
animals, serum IgE 4 wk after infection was 13.2 6 2.0
mg/ml (n 5 4 mice).
Effect of Anti–IL-12. IL-12 appears likely to be the key
endogenous initiator of the cell-mediated immune response
which underlies experimental defense against a number of
pathogens including L. donovani (28, 44). Therefore, to ex-
plore an alternative approach to establishing a Th2 re-
sponse, BALB/c mice were treated with anti–IL-12 to in-
hibit the initiation of the Th1 mechanism, suppress the
principal inducer of endogenous IFN-g, and permit cytokines
such as IL-4 and IL-10 to emerge and act unopposed (33,
34, 39). In an initial study of L. donovani–infected BALB/c
mice, three injections of anti–IL-12 during the first week
after challenge were sufficient to largely prevent control of
visceral infection at week 4 (28). In the current experi-
ments, we modified this protocol by (a) injecting BALB/c
mice with anti–IL-12 starting 2 h after L. donovani chal-
lenge and then three times per week for 2 wk (rather than
for 1 wk; 28), and then (b) observing the animals for a
longer period after the last anti–IL-12 treatment. Although
anti–IL-12 administration during weeks 1 and 2 exacer-
bated visceral infection at week 4 (Fig. 1 D), these mice
nonetheless proceeded to control parasite replication and
reduced liver burdens by week 8.
Effect of Increasing the Challenge Inoculum. BALB/c mice
are remarkably susceptible to L. major and develop unre-
lenting infection related to induction of a particularly in-
tense Th2 response (12, 13, 45). These events have been
linked in part to the size of the original challenge inocu-
lum, because cutaneous infection is controlled when lower
numbers of L. major are initially used (46). Therefore, as-
suming that injecting high numbers of parasites may facili-
tate induction or enhance the activity of an expressed but
nonfunctional Th2 response (26), next we challenged BALB/c
animals with 10–20-fold more amastigotes (1 and 2 3 108)
than used in the standard L. donovani inoculum (107). How-
ever, after four weeks, visceral infection was controlled in a
simliar fashion in all three dose groups (Fig. 1 E).
Effect of Pretreatment with HKLMP. Finally, we tested
whether BALB/c mice could be induced by presensitiza-
tion with four once-per-week injections of HKLMP to
cross-react to L. donovani with a Th2-associated response.
This technique provokes a disease-exacerbating effect upon
subsequent infection with live L. major (35). In a prelimi-
nary experiment, mice pretreated with four once-per-week
injections of saline alone controlled and eradicated L. dono-
vani; 4 wk after infection, mean (6 SEM) liver parasite
burdens were 1,144 6 86 versus 947 6 61 in uninjected
controls, and at week 8, were 241 6 26 versus 260 6 31,
respectively (n 5 4 mice per group at each time point). In
contrast, mice pretreated in a similar fashion with HKLMP
failed to express acquired resistance 2 wk after L. donovani
challenge, and liver burdens at week 4 were 3.2-fold higher
than in control mice (Fig. 2). Visceral infection in HKLMP-
treated mice then plateaued, and liver parasite burdens re-
mained high at week 8 (8.7-fold greater than in untreated
controls).
Figure 1. Preliminary experiments to determine the course of visceral infection in five different populations of mice. (A) BALB/c mice not treated (d)
or injected once with IL-4/anti–IL-4 complex one day before (day 21) L. donovani challenge (s). (B) BALB/c mice not treated (d) or injected with
IL-4/anti–IL-4 starting on day 21 and twice per week for the first four weeks after challenge (s). (C) Control 129/Sv/Ev (d) and 129/Sv/PEP IL-4
transgenic mice (s). (D) BALB/c mice treated three times per week for 2 wk with normal sheep IgG (d) or sheep anti–IL-12 IgG (s) starting 2 h after
challenge. (E) BALB/c mice challenged with 107 (d) or 2 3 107 (s) amastigotes. In mice challenged with 2 3 108 amastigotes, week 8 LDU were 761 6
61 (n 5 4 mice). Results in A–E indicate mean values (SE ,16% in each case) from the single experiment performed with 4–5 mice per group. Note
different vertical axis scale in B and C.870 Effect of Th2 Response on Visceral L. donovani Infection
Responses in HKLMP-treated BALB/c Mice
Induction of an Active Th2-associated Cytokine Response.
In normal unmanipulated BALB/c mice, L. donovani infec-
tion induces both IL-4 and IL-10 mRNA expression in the
liver and serum IgE levels increase as well (26). Neverthe-
less, we concluded that this Th2 response is not functional
and/or is rapidly overshadowed by a Th1 mechanism in
normal mice since treatment with anti–IL-4 (26) or anti–
IL-10 (unpublished) does not affect the kinetics of visceral
infection and resistance is acquired (22, 26). In contrast, as
judged by overt increases in serum IgE levels both before
and after L. donovani challenge (Table 1), and more impor-
tantly, by the effects of injecting anti–IL-4 and anti–IL-10,
HKLMP-primed mice showed clear-cut evidence of an ac-
tive, disease-promoting Th2-associated cytokine response.
As shown in Fig. 3, treatment with either anti–IL-4 or
anti–IL-10 permitted HKLMP-sensitized mice to exert es-
sentially normal control over intracellular visceral infection
at week 4. Thus, whereas both IL-4 and IL-10 were re-
quired, neither by itself appeared sufficient to mediate the
suppressive, antihost defense effect of the provoked Th2
response. We concluded from these results that IL-4 and
IL-10 likely acted in concert in this model.
Effect on the Tissue Immune Response. Since successful re-
sistance to L. donovani in BALB/c mice is expressed in the
tissues by granuloma formation (22, 47), we also examined
liver sections from HKLMP-pretreated animals. In normal
BALB/c mice, granuloma assembly in the liver proceeds in
an orderly fashion; each infected focus, consisting initially
of single, infected resident macrophages (Kupffer cells),
gives rise to a core of fused parasitized Kupffer cells which
comes to be surrounded by a mononuclear cell mantle
comprised of influxing T cells and monocytes (22, 27, 47).
This histologic reaction is detectable by week 2 after chal-
lenge and is fully developed by or after week 4 (22, 47).
The early tissue reaction to L. donovani at week 2 was simi-
lar in HKLMP-treated and control BALB/c animals: (a) no
cellular reaction was present at 32 6 6% versus 40 6 4% of
infected foci, respectively; (b) developing granulomas were
present at 56 6 8% versus 48 6 7% of sites; and (c) 12 6
1% versus 12 6 2% of foci were scored as mature granulo-
mas (two experiments, n 5 4 mice). However, after week
2, responses diverged. While normal mice converted the
bulk of infected foci to mature granulomas by week 8,
HKLMP-primed mice did not, and in these animals the tis-
sue reaction failed to properly progress to yield formed
granulomas at the majority of infected sites (Fig. 4). In nor-
mal BALB/c mice, single parasitized Kupffer cells with no
surrounding mononuclear cell reaction were seldom en-
Figure 2. Course of visceral infection in HKLMP-primed BALB/c
mice. Mice were not pretreated (d) or were injected with HKLMP (s)
once per week for 4 wk before being challenged with L. donovani 7 d
later. Results are from four to five experiments, and indicate mean 6
SEM values for 12–20 mice at each time point.
Table 1. Serum IgE Levels before and after L. donovani Infection*
Pretreatment of
BALB/c mice Week
Serum IgE
024 8
m g/ml
Experiment 1
None (control) 0.6 6 0.1 1.8 6 0.3 4.0 6 0.9 5.3 6 1.2
HKLMP 6.2 6 4.1 4.7 6 0.4 15.3 6 1.8 26.2 6 3.7
Experiment 2
None (control) 1.7 6 0.4 3.9 6 0.9 5.8 6 0.8 18.8 6 2.7
HKLMP 17.9 6 2.9 13.9 6 1.8 41.5 6 8.9 97.8 6 14.1
*Mice received no pretreatment or once-per-week injections of HKLMP for 4 wk before L. donovani challenge. Week 0 indicates samples obtained
just before L. donovani infection. Results are mean 6 SEM values for three to four mice per group.871 Murray et al.
countered 4 (3 6 1%) or 8 wk (1 6 1%) after infection
(two experiments, n 5 4 mice). Thus, observing little or no
histologic reaction at these latter two time points at 23 6
4% and 29 6 5% of parasitized foci in HKLMP-primed
mice also demonstrated the extent of inhibition of mono-
nuclear cell recruitment (Fig. 5). Together, these data em-
phasized the overall failure of granuloma assembly in this
Th2 response environment.
Effect of Prophylactic and Therapeutic Administration of Th1-
associated Cytokines IL-12 and IFN-g. We concluded the
experiments in HKLMP-sensitized mice by asking (a) whether
the induced Th2 response was reversible by early (prophy-
lactic) treatment with IL-12 or IFN-g, two Th1-associated
cytokines with well-recognized antileishmanial effects (34,
37–39), and (b) could exogenous IL-12 or IFN-g also in-
duce activity once the Th2 response and visceral infection
were well established. Consistent with earlier results de-
rived from L. major–infected BALB/c mice (34, 39), early
treatment with IL-12 (days 11 to 17) entirely reversed the
inability of HKLMP mice to control visceral infection mea-
sured at week 4 (Table 2). However, in the same experi-
ments, prophylactic treatment with IFN-g had considerably
less effect. Nevertheless, when given as therapy in HKLMP-
sensitized mice with firmly established infection, both IL-12
and IFN-g induced antileishmanial activity (Table 2) at a
level comparable to that achieved in parallel studies carried
out in normal BALB/c mice (37, 48). While the effect of
cytokine treatment in Table 2 is expressed as percentage in-
hibition of parasite replication, both IFN-g and, to a con-
siderably greater extent, IL-12, also induced leishmanicidal
effects. In cytokine-treated HKLMP-primed mice, liver
parasite burdens were reduced by 26% (IFN-g) and 55%
(IL-12) at the end of 7 d of cytokine administration (week
3 versus 4 LDU).
Discussion
These results in HKLMP-primed BALB/c mice (a) de-
scribe a model for studying visceral L. donovani in a pre-
Figure 3. Effect of anti–IL-4 or anti–IL-10 treatment on visceral infec-
tion of HKLPM-primed mice. BALB/c mice were pretreated once per
week for 4 wk with HKLMP and then challenged with L. donovani. The
day before challenge and once per week thereafter for 4 wk, mice re-
ceived no further treatment (filled bar), injections of control antibody
(hatched bar), or anti-cytokine mAb (open bar). Results are from two ex-
periments, and indicate mean 6 SEM LDU values for six to seven mice
per group.
Figure 4. Inhibition of granuloma assembly in HKLMP-primed BALB/c
mice. Liver sections from untreated control (d) and HKLPM-primed
mice (s) were examined for infected foci. All foci in 50 consecutive 363
microscopic fields were scored as follows for granuloma formation: none,
single or fused parasitized Kupffer cells with no mononuclear cell infil-
trate; developing granuloma, core of fused infected Kupffer cells with
some cell infiltrate; or mature granuloma, fused Kupffer cell core sur-
rounded by a well-developed mononuclear cell mantle (22, 27). Results
are from two experiments, and indicate mean 6 SEM values for four
mice (see Fig. 5).
Figure 5. Photomicrograph of
liver sections from untreated
control (A) and HKLMP-primed
BALB/c mice (B) 4 wk after L.
donovani infection. (A) shows a
large, well-developed mature
granuloma at an infected focus in
normal mice. The granuloma
contains few amastigotes. In B,
HKLMP-primed mice show
fused, heavily parasitized Kupffer
cells (arrows), but little or no sur-
rounding mononuclear cell infil-
trate. 3200.872 Effect of Th2 Response on Visceral L. donovani Infection
dominant Th2-associated response environment, (b) not
unexpectedly demonstrate that this response inhibits the
capacity to acquire effective antileishmanial resistance mea-
sured by tissue parasite burden and granuloma assembly,
and (c) suggest that the disease-exacerbating mechanism in
this model requires the participation of both IL-4 and IL-10.
Among other actions, IL-4 is thought to be primarily re-
sponsible for expanding the Th2 response (12, 13, 31, 41);
both IL-4 and -10 are capable of suppressing the secretion
and macrophage-activating effects of Th1-associated cyto-
kines including IFN-g (4, 12, 13, 31, 41–43, 49, 50).
While some of our observations, including the efficacy of
prophylactic IL-12 (34, 39), mirror lessons already learned
from models of infection caused by L. major and L. mexi-
cana (12, 13, 16–19, 31, 33, 41), two findings differ. First,
although endogenous IL-4 clearly played a resistance-inhib-
iting role in HKLMP-primed BALB/c mice, 129/Sv IL-4
transgenic mice showed no difficulty in controlling visceral
L. donovani. We suspect these results indicate that sustained
IL-4 secretion by itself may not be sufficient to overcome
the innate resistance (20) imparted by the 129/Sv back-
ground of the transgenic animals. However, we did not di-
rectly measure IL-4 production, nor investigate other cy-
tokine or cellular responses in infected transgenic mice;
thus, potentially suboptimal IL-4 production (30), insuffi-
cient cofactor (IL-10) secretion, or the remote possibility of
a simultaneously enhanced Th1 response also remain as
other potential explanations for our observations.
Second, both IL-12– and IFN-g–induced visceral antile-
ishmanial activity in the face of an established, disease-exac-
erbating Th2-associated cytokine response. This new finding
contrasts directly with treatment data derived from models
of established L. major cutaneous infection in BALB/c mice
in which neither exogenous IL-12 nor IFN-g achieved an-
tileishmanial activity (34, 39, 51). There are a number of
possible explanations for these differing observations includ-
ing the pathogens themselves, the site where infection is
introduced, the requirement in the L. donovani model for
prechallenge manipulation (sensitization), the heterogeneity
and/or intensity of a naturally-occurring versus a provoked,
cross-reacting type of Th2 response, and the timing and
doses of cytokine treatment used. Nevertheless, experience
in other models has also raised the possibility of overriding
at least some components of an established Th2 response
using exogenous IL-12 (52–59). In addition, treatment with
IFN-g alone can also induce measureable antileishmanial
activity in patients with visceral leishmaniasis who also ex-
press a Th2 response (9, 60).
Finally, it is worth noting that in HKLPM-primed mice,
exogenous IL-12 was considerably more active than IFN-g
when used either prophylactically or as treatment. Since this
study did not include analysis of the mechanisms underly-
ing the efficacy of IL-12 or IFN-g in HKLMP-primed mice,
we have not identified which prohost defense pathway was
enhanced or which suppressive pathway was inhibited.
However, because exogenous IL-12 readily induces IFN-g
(37), the enhanced effect of IL-12 in established infection
(Table 2) suggests that in addition to macrophage activation
stimulated by endogenous IFN-g (38), multiple antileish-
manial actions may mediate the efficacy of IL-12 in HKLMP-
treated mice. These effects might include the capacity of
IL-12 to expand other Th1-related mechanisms, suppress
the deactivating effects of IL-4 and -10, and perhaps en-
hance the activity of natural killer cells (44).
Table 2. Effect of IL-12 and IFN-g Treatment in
HKLMP-primed BALB/c Mice*
Treatment of
HKLMP-
primed mice
Liver parasite burden
% Inhibition
of Replication‡ Day 121 128
LDU
Day 11 to 17
None (see below) 2,561 6 170 2
Saline NT§ 2,682 6 101 0
IL-12 NT 546 6 931 79
IFN-g NT 1,893 6 107 26
Day 121 to 128
None 1,761 6 132 2,561 6 170 2
Saline 2 2,351 6 97 8
IL-12 2 767 6 6311 70
IFN-g2 1,267 6 1391 51
*BALB/c mice were pretreated for 4 wk with HKLMP, challenged
with L. donovani, and received either no treatment or were subsequently
treated for 7 d with pump-administered saline, IL-12 (1 mg/d), or IFN-g
(2 3 105 U/d). 7-d pumps were implanted either 4 h after challenge or
not until 3 wk later (day 121). All treated mice were killed on day
128. Results are from two (IL-12) to three experiments (IFN-g), and
indicate mean 6 SEM values for 6–10 mice per group.
‡Compared to day 128 LDU in untreated control mice.
§NT, not tested
1P ,.05 versus untreated controls on day 128.
11P ,.05 versus untreated controls on both 121 and 128.
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